Skip to main content

Day: April 28, 2025

Šiaulių Bankas Group results for 3M 2025

Profit. Šiaulių Bankas Group earned a net profit of €17.7 million Fee and commission income. Net fee and commission income exceeded €7.5 million, up 17% year-on-year Loan portfolio. The loan portfolio exceeded €3.5 billion, up 15% year-on-year Financing structure. The bank successfully placed €300 million bond issue on the international markets Buybacks. The bank has requested the ECB for authorisation to purchase 4.5 million of own shares Rebranding. Šiaulių Bankas will become Artea as of 5 May 2025.  “We are about to take a historic step by becoming Artea in early May. This is more than just a new name. It is a strategic initiative to strengthen our relationship with private and corporate clients, the public and investors, and to become the first choice bank for customers in Lithuania. We are fully focused on this important...

Continue reading

Jade Biosciences Completes Closing of Merger with Aerovate Therapeutics and Previously Announced Private Placement of Approximately $300 Million

Company is advancing portfolio of novel therapies that aim to redefine the standard of care for patients with autoimmune diseases Lead candidate JADE-001 on track to enter the clinic in second half of 2025, with initial data expected in first half of 2026 The combined company will operate as “Jade Biosciences, Inc.” and will trade on Nasdaq under the ticker symbol “JBIO” SAN FRANCISCO and VANCOUVER, British Columbia, April 28, 2025 (GLOBE NEWSWIRE) — Jade Biosciences, Inc. (“Jade” or the “Company”), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced the completion of its previously announced merger with Aerovate Therapeutics, Inc. (“Aerovate”). The combined company will operate as Jade Biosciences, Inc., with its shares expected to begin trading on the Nasdaq Capital...

Continue reading

Coherus Presents Promising Early Clinical Data from Phase 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025

– CHS-114 demonstrates clinical efficacy and proof of mechanism in HNSCC in combination with toripalimab – – Confirmed partial response in heavily pretreated PD-1 refractory patient supports expansion in HNSCC and gastric cancer in combination with toripalimab – – A second-line Phase 1 dose optimization study in HNSCC and gastric cancer is ongoing; results expected in the first half of 2026– – Coherus to host investor and analyst call with study investigator, Dr. Douglas Adkins, Washington University, today at 4:30 p.m. Eastern Time– REDWOOD CITY, Calif., April 28, 2025 (GLOBE NEWSWIRE) — Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS), today announced data from its ongoing Phase 1 clinical trial evaluating CHS-114, a selective, cytolytic anti-CCR8 antibody, as monotherapy and in combination with toripalimab in patients with...

Continue reading

A New Name. A Global Mission. Introducing SafeSpace Global Corporation

Knoxville, TN, April 28, 2025 (GLOBE NEWSWIRE) — Healthcare Integrated Technologies is proud to announce a major milestone in its evolution: the Company has officially rebranded as SafeSpace Global Corporation (OTC PINK: SSGC). This transformation represents far more than a new name, it signals the powerful expansion of the company’s mission, technology, and global reach. What began as a focused initiative to protect lives in senior living and healthcare has grown into a broader, more urgent calling: to deliver life-saving ambient AI safety solutions to the world. Scott Boruff, CEO of SafeSpace Global Corporation, founded the Company in 2016 with a focus on helping save lives in Senior Living Facilities. SafeSpace now helps save lives with it’s patented ambient AI technology ranging from schools to transit systems, prisons to commercial...

Continue reading

CORRECTION — IRADIMED CORPORATION to Hold First Quarter of 2025 Financial Results Conference Call on May 5, 2025

WINTER SPRINGS, Fla., April 28, 2025 (GLOBE NEWSWIRE) — In a release issued under the same headline earlier today by IRADIMED CORPORATION (NASDAQ: IRMD), please note that in the first paragraph the date of the earnings call should read “Monday, May 5, 2025” instead of “Friday, May 5, 2025”.  The corrected release follows: IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2025 first quarter financial results before the market opens on Monday, May 5, 2025. Iradimed management will host a conference call the same day beginning at 9:00 a.m. Eastern Time to discuss those results and to answer questions. Individuals interested in participating in the conference call may do so by registering here, https://register-conf.media-server.com/register/BI1cddc009ba2b427a81ea445f5669adffOnce...

Continue reading

Getty Images and Ancestry Partner to Digitally Preserve Historic Archives of HBCUs

Ancestry will work with HBCUs to preserve their historical documents and rarely seen photographyA Media Snippet accompanying this announcement is available by clicking on this link. NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) — Getty Images (NYSE: GETY), a preeminent global visual content creator and marketplace, has announced a first-of-its-kind genealogy-focused partnership with Ancestry, the global leader in family history. As part of Getty Images’ HBCU Grants Program, this initiative will focus on the digital preservation and accessibility of historical documents, records and the photographic archives of Historically Black Colleges and Universities (HBCUs). Once digitized, these invaluable archives will become searchable on Ancestry websites, helping millions of people discover and connect with the rich legacy of HBCUs. Working...

Continue reading

Park Street A/S announces results of annual general meeting 2025

Park Street A/S announces results of annual general meeting 2025 Park Street A/S Results of annual general meeting Results of Park Street A/S’ annual general meeting 2025 Today, Park Street A/S held its annual general meeting 2025 in accordance with the notice and the agenda announced on 4 April 2025.  The following resolutions were adopted:Approval of the audited annual report for the financial year 2024.Approval of the results in accordance with the approved annual report for the financial year 2024 being carried over to the financial year 2025.Approval of the remuneration report for the financial year 2024.Resolution to reduce the share capital with a nominal amount of DKK 13,794,324 by annulment of treasury shares as set out in the notice.Re-election of Anita Nassar, Pradeep Pattem, Ohene Aku Kwapong, Claes Peter...

Continue reading

Citizens Community Bancorp, Inc. Reports First Quarter 2025 Earnings of $0.32 Per Share; Book Value Per Share Up 8% and Tangible Book Value Per Share Up 10% Since March 31, 2024, After Annual Dividend Payment of $0.36 Per Share

EAU CLAIRE, Wis., April 28, 2025 (GLOBE NEWSWIRE) — Citizens Community Bancorp, Inc. (the “Company”) (Nasdaq: CZWI), the parent company of Citizens Community Federal N.A. (the “Bank” or “CCFBank”), today reported earnings of $3.2 million and earnings per diluted share of $0.32 for the first quarter ended March 31, 2025, compared to $2.7 million and earnings per diluted share of $0.27 for the fourth quarter ended December 31, 2024, and $4.1 million and $0.39 earnings per diluted share for the quarter ended March 31, 2024, respectively. The Company’s first quarter 2025 operating results reflected the following changes from the fourth quarter of 2024: (1) decrease in net interest income of $0.1 million as two fewer days in the quarter were largely offset by an increase in the net interest margin of 6 basis points; (2) a smaller negative...

Continue reading

Endeavor Bancorp Reports Net Income of $1.4 Million for the First Quarter of 2025; Highlighted by Loan and Deposit Growth and Net Interest Margin Expansion

SAN DIEGO, April 28, 2025 (GLOBE NEWSWIRE) — Endeavor Bancorp (OTCQX: EDVR) (the “Company,” or “Bancorp”), the holding company for Endeavor Bank (the “Bank”), today reported net income of $1.36 million, or $0.32 per diluted share, for the first quarter of 2025, compared to net income of $1.08 million, or $0.25 per diluted share, for the fourth quarter of 2024, and $407,000, or $0.10 per diluted share, for the first quarter of 2024. First Quarter 2025 financial results are unaudited. Results for the first quarter of 2025 included a $385,000 provision for credit losses, compared to a $374,000 provision for credit losses in the fourth quarter of 2024, and a $450,000 provision for credit losses in the first quarter of 2024. Excluding taxes and loan loss provisions, the Company’s pretax, pre-provision net income increased to $2.33 million...

Continue reading

FEMSA Announces First Quarter 2025 Results

MONTERREY, Mexico, April 28, 2025 (GLOBE NEWSWIRE) — Fomento Económico Mexicano, S.A.B. de C.V. (“FEMSA”) (NYSE: FMX; BMV: FEMSAUBD, FEMSAUB) announced today its operational and financial results for the first quarter of 2025.FEMSA: Total Consolidated Revenues grew 11.1% and Income from Operations increased 4.9% compared to 1Q24. FEMSA Retail1: Proximity Americas total Revenues grew 6.8% and Income from operations decreased 11.8% versus 1Q24. SPIN: Spin by OXXO had 8.9 million active users2 representing 20.9% growth compared to 1Q24 while Spin Premia had 25.2 million active loyalty users2 representing 15.9% growth compared to 1Q24, and an average tender3 of 42.5% which increased from 35.1% tender in 1Q24. COCA-COLA FEMSA: Total Revenues and Income from Operations grew 10.0% and 7.4%, respectively against 1Q24.Financial Summary...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.